Can Buscopan Worsen Constipation?
Yes, Buscopan (hyoscine butylbromide) can worsen constipation due to its anticholinergic mechanism of action, which reduces intestinal motility. This is a well-recognized effect of antimuscarinic antispasmodics and should be carefully considered when prescribing, particularly in patients where constipation is already a prominent symptom.
Mechanism Behind Constipation Risk
Buscopan is an anticholinergic antispasmodic that works by blocking muscarinic receptors (primarily M2 and M3) on gastrointestinal smooth muscle 1, 2. While this mechanism effectively reduces intestinal spasm and cramping pain, it simultaneously:
- Reduces intestinal motility by blocking the cholinergic stimulation needed for normal peristalsis
- Slows colonic transit time through its antimuscarinic effects 3
- Decreases the propulsive contractions necessary for normal bowel movements
The drug's anticholinergic properties are the same reason it provides pain relief, but this comes at the cost of potentially slowing bowel function 4.
Clinical Guideline Recommendations
Multiple gastroenterology guidelines explicitly acknowledge this constipating effect:
The 2022 AGA guidelines note that "regular use in constipation may be limited due to its anticholinergic effects" 5. This is a conditional recommendation recognizing that while antispasmodics can help with pain, their use must be balanced against bowel habit effects.
The 2016 NCCN Palliative Care guidelines specifically list "anticholinergic drugs (antidepressants, antispasmodics, phenothiazines, and haloperidol)" among medications known to cause constipation 6. The guidelines recommend discontinuing nonessential constipating medications when managing constipation.
The 2018 ESMO guidelines on constipation in advanced cancer similarly identify medications with anticholinergic actions, including antispasmodics, as common constipating drugs 7.
The 2020 BSG guidelines on intestinal dysmotility discuss hyoscine butylbromide as an antispasmodic but note it is used for pain management, not for improving motility 4.
Clinical Context: When to Avoid or Use Cautiously
Avoid in:
- IBS with constipation predominance (IBS-C): The 2021 BSG IBS guidelines recommend tricyclic antidepressants "are best avoided if constipation is a major feature" 8, and this same principle applies to anticholinergic antispasmodics
- Patients already taking opioids: Since opioids already cause significant constipation, adding an anticholinergic can compound the problem 6
- Chronic constipation: Adding a motility-slowing agent is counterproductive
May be appropriate in:
- IBS with diarrhea (IBS-D): The constipating effect may actually be beneficial in patients with loose stools 1
- Acute cramping pain without constipation: Short-term use for symptom relief when constipation is not present
- Biliary or renal colic: Where the antispasmodic effect is the primary goal 9
Practical Management Approach
If prescribing Buscopan:
- Screen for baseline constipation - Ask about current bowel frequency and consistency
- Review concurrent medications - Check for other constipating drugs (opioids, other anticholinergics)
- Consider IBS subtype - Use preferentially in IBS-D, avoid in IBS-C
- Prophylactic laxatives - If Buscopan is necessary in someone at risk, consider concurrent stimulant laxatives 6
- Monitor bowel function - Reassess after starting treatment
Alternative antispasmodics with potentially less constipating effect:
- Peppermint oil: Direct smooth muscle relaxant without anticholinergic effects 10, 5
- Mebeverine or alverine: Direct-acting smooth muscle relaxants rather than antimuscarinics 1
Common Pitfall
The most significant clinical error is prescribing Buscopan to patients with IBS-C or those already struggling with constipation, where the anticholinergic effects will exacerbate their primary symptom. The drug's effectiveness for pain relief can mask the worsening constipation until it becomes severe. Always assess predominant bowel pattern before prescribing any anticholinergic antispasmodic.